- PacBio (PACB, Financial) appoints Haorui Gene as an official distributor in China, expanding their HiFi long-read sequencing technology network.
- Haorui Gene has established a strong presence in China's genomics market, deploying multiple PacBio systems and publishing over 20 peer-reviewed papers.
- The distribution agreement focuses on transfusion medicine and hematology, leveraging PacBio's Vega platform to enhance clinical applications.
PacBio (PACB), a leader in high-quality sequencing solutions, has announced a strategic partnership with Haorui Gene, a recognized innovator in blood typing genomics, to expand their distribution network in China. This collaboration marks an important milestone for PacBio as Haorui Gene will distribute their HiFi long-read sequencing technology across clinical and research settings in China, with a particular focus on transfusion medicine and hematology.
Founded in 2020, Haorui Gene has rapidly become a key player in the genomics sector by deploying seven Sequel II and three Revio systems across various blood centers in China. This deployment supports large-scale initiatives in HLA typing, blood group genotyping, and the discovery of rare blood types. The company’s efforts have been well-documented through over 20 peer-reviewed publications, highlighting their expertise and influence in the field.
The agreement between PacBio and Haorui Gene includes the distribution of PacBio's Vega platform, aiming to enhance the precision and completeness of genomic data crucial for patient outcomes. By targeting high-value clinical applications, this partnership leverages Haorui's established network and proven track record to further integrate PacBio's technology in new customer segments, including hospital labs and regional blood centers.
This move is strategically important for PacBio, providing them with a strong foundation in one of the fastest-growing clinical genomics markets globally. It underscores a shared commitment to making high-precision sequencing more accessible and standard in healthcare applications that require accuracy at scale. This partnership is anticipated to accelerate the adoption of PacBio’s technologies in China, driving further growth and innovation in the genomics industry.
